Commercializationv2 · 10.13
Investing in another company's drug to advance your own ↗
Read the background →Investing in another company's drug to advance your ownLatest update →BioNTech: mRNA cancer immunotherapy combination misses PFS endpoint; survival evaluation continues
How are costs, rights and returns shared when another company’s technology enables a treatment?
The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.
- PFS result announcedRecorded
- Prespecified OS assessmentUnverified
- Detailed resultsUnverified
Additional source checked
Added the BNT113 PFS result and continuation of the prespecified OS assessment.
NEXT CHECK
The planned OS analysis, detailed PFS results, and explanations of the population and safety findings.
Evidence: www.astrazeneca.com ↗smmttx.com ↗